Milestone Pharmaceuticals Inc Cash Flow Conversion Efficiency
Milestone Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has a cash flow conversion efficiency ratio of -0.479x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.82 Million) by net assets ($20.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Milestone Pharmaceuticals Inc (2017–2024)
Cash flow conversion efficiency of Milestone Pharmaceuticals Inc from 2017 to 2024. This chart illustrates how Milestone Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Milestone Pharmaceuticals Inc (MIST) stock price for real-time trading data and today's change.
Milestone Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Milestone Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Milestone Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Milestone Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thantawan Industry Public Company Limited
BK:THIP
|
-0.005x |
|
Halla Eng&Cons
KO:014790
|
-0.073x |
|
Kingstate Electronics
TWO:3206
|
0.095x |
|
Malee Group Public Company Limited
BK:MALEE
|
0.047x |
|
ENERGY TRANSITION MINERAL
F:G7PA
|
N/A |
|
GFL Limited
NSE:GFLLIMITED
|
0.000x |
|
Kumho Electric
KO:001210
|
-0.534x |
|
Medicalg
WAR:MDG
|
0.019x |
Annual Cash Flow Conversion Efficiency for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Milestone Pharmaceuticals Inc from 2017 to 2024. Review MIST cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.15 Million | $-28.85 Million | -2.194x | +20.73% |
| 2023-12-31 | $16.77 Million | $-46.42 Million | -2.768x | -250.03% |
| 2022-12-31 | $66.35 Million | $-52.47 Million | -0.791x | -168.02% |
| 2021-12-31 | $112.60 Million | $-33.22 Million | -0.295x | +16.76% |
| 2020-12-31 | $143.12 Million | $-50.73 Million | -0.354x | +20.36% |
| 2019-12-31 | $114.92 Million | $-51.15 Million | -0.445x | -216.77% |
| 2018-12-31 | $-55.21 Million | $-21.05 Million | 0.381x | +56.79% |
| 2017-12-31 | $-33.12 Million | $-8.05 Million | 0.243x | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more